Sutro Biopharma (STRO) Operating Leases (2021 - 2025)

Sutro Biopharma has disclosed Operating Leases across 5 years of filings, most recently posting $7.9 million for Q4 2025.

• Operating Leases for Q4 2025 came in at $7.9 million, down 49.66% year-over-year; the trailing twelve-month figure through Dec 2025 was $7.9 million (down 49.66% YoY), and the FY2025 annual result was $7.9 million, down 49.66% from the prior year.
• Operating Leases came in at $7.9 million for Q4 2025 at Sutro Biopharma, down from $9.7 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $32.1 million in Q3 2021 to a low of $7.9 million in Q4 2025.
• The 5-year median for Operating Leases is $24.0 million (2023), against an average of $22.6 million.
• Across the five-year window, Operating Leases retreated 3.23% in 2022 and plunged 49.66% in 2025, its largest moves.
• Sutro Biopharma's Operating Leases stood at $31.2 million in 2021, then retreated by 5.28% to $29.6 million in 2022, then retreated by 21.71% to $23.2 million in 2023, then slumped by 32.31% to $15.7 million in 2024, then slumped by 49.66% to $7.9 million in 2025.
• The last three Operating Leases figures came in at $7.9 million (Q4 2025), $9.7 million (Q3 2025), and $11.5 million (Q2 2025), per Business Quant data.